Company intelligence / Profile preview

BloodScan Biotech

Ann Arbor, Michigan, USAbloodscanbiotech.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

BloodScan Biotech is a University of Michigan spin-out focused on developing next-generation liquid biopsy technology for non-invasive cancer diagnostics. Its flagship platform, Labyrinth One, enables high-purity, label-free isolation of circulating tumor cells from blood samples in under 15 minutes. The company aims to improve early cancer detection and disease monitoring by leveraging advanced microfluidic engineering.

Therapeutic areas: OncologyOther
Modalities: Liquid biopsy technologyMicrofluidic devices for cell isolation and analysis
Industry: Molecular Diagnostics

Partnerships

University of Michigan – technology transfer agreement for microfluidic device commercialization.Taiwanese hardware manufacturers

Beyond the preview

Go deeper on BloodScan Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BloodScan Biotech.

Explore the full profile